Subcutaneously delivered natalizumab for the treatment of highly active relapsing-remitting multiple sclerosis

Česká verzia

Authors: S. Halúsková; M. Vališ
Authors place of work: Neurologická klinika LF UK a FN Hradec Králové
Published in the journal: Cesk Slov Neurol N 2022; 85(3): 206-212
Category: Review Article
doi: https://doi.org/10.48095/cccsnn2022206

Summary

Therapeutic monoclonal antibodies (MAbs) have become one of the fastest growing classes of drugs, approved for the treatment of a wide range of indications. The development of new humanized and fully human MAbs has vastly improved their safety profile. Natalizumab is a humanized anti-α4-integrin monoclonal antibody, indicated as a single disease modifying therapy in adults with highly active relapsing-remitting multiple sclerosis. In 2021, natalizumab was authorized for use also as a subcutaneous injection. Clinical trials have shown that monthly subcutaneous injections of natalizumab are as safe and clinically and radiologically effective as monthly intravenous infusions.

Keywords:

Multiple sclerosis – Monoclonal antibodies – natalizumab – treatment – subcutaneous administration

Zdroje

1. Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol 2018; 31(6): 752–759. doi: 10.1097/ WCO.0000000000000622.

2. Atlas of MS 3rd edition. 2020. Available from URL: https:/ / www.msif.org/ wpcontent/ uploads/ 2020/ 10/ Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9- 20.pdf.

3. Havrdova E, Galetta S, Hutchinson M et al. Eff ect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Effi cacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009; 8(3): 254–260. doi: 10.1016/ S1474-4422(09)70021-3.

4. Lu G, Beadnall HN, Barton J et al. The evolution of „No Evidence of Disease Activity“ in multiple sclerosis. Mult Scler Relat Disord 2018; 20: 231–238. doi: 10.1016/ j.msard.2017.12.016.

5. Phillips JT, Giovannoni G, Lublin FD et al. Sustained improvement in Expanded Disability Status Scale as a new effi cacy measure of neurological change in multiple sclerosis: treatment eff ects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler 2011; 17(8): 970 –979. doi: 10.1177/ 1352458511399611.

6. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefi ned specifi city. Nature 1975; 256(5517): 495–497. doi: 10.1038/ 256495a0.

7. Foltz IN, Karow M, Wasserman SM. Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know. Circulation 2013; 127(22): 2222–2230. doi: 10.1161/ CIRCULATIONAHA.113.002033.

8. Mullard A. FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov 2021; 20(7): 491–495. doi: 10.1038/ d41573-021-00079-7.

9. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs 2015; 7(1): 9–14. doi: 10.4161/ 19420862.2015.989042.

10. Huggett B. How Tysabri survived. Nat Biotechnol 2009; 27(11): 986. doi: 10.1038/ nbt1109-986.

11. Williamson EML, Berger JR. Dia gnosis and treatment of progressive multifocal leukoencephalopathy associated with multiple sclerosis therapies. Neurotherapeutics 2017; 14(4): 961–973. doi: 10.1007/ s13311-017-0570-7.

12. Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354(9): 911–923. doi: 10.1056/ NEJMoa044396.

13. Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn‘s disease. N Engl J Med 2005; 353(4): 362–368. doi: 10.1056/ NEJMoa051586.

14. Clerico M, Artusi CA, Liberto AD et al. Natalizumab in multiple sclerosis: long-term management. Int J Mol Sci 2017; 18(5): 940. doi: 10.3390/ ijms18050940.

15. Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005; 64(8): 1336–1342. doi: 10.1212/ 01.WNL.0000158329.30470.D0.

16. Polman CH, O‘Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354(9): 899–910. doi: 10.1056/ NEJMoa044397.

17. Butzkueven H, Kappos L, Wiendl H et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry 2020; 91(6): 660–668. doi: 10.1136/ jnnp- 2019-322326.

18. Horakova D, Uher T, Krasensky J et al. Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: a longitudinal, retrospective study. Mult Scler Relat Disord 2020; 46: 102543. doi: 10.1016/ j.msard.2020.102543.

19. Klotz L, Havla J, Schwab N et al. Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord 2019; 12: 1756286419836571. doi: 10.1177/ 1756286419836571.

20. Singer BA. The role of natalizumab in the treatment of multiple sclerosis: benefi ts and risks. Ther Adv Neurol Disord 2017; 10(9): 327–336. doi: 10.1177/ 1756285617716002.

21. Štourač P, Bednářová J, Pavelek Z. Etiopatogeneze a dia gnostika progresivní multifokální leukoencefalopatie u pacientů léčených natalizumabem. Cesk Slov Neurol N 2021; 84/ 117(2): 135–138. doi: 10.48095/ cccsnn2021 135.

22. Foley JF, Goelz S, Hoyt T et al. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing. Mult Scler Relat Disord 2019; 31: 65–71. doi: 10.1016/ j.msard. 2019.03.017.

23. Plavina T, Muralidharan KK, Kuesters G et al. Reversibility of the eff ects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology 2017; 89(15): 1584–1593. doi: 10.1212/ WNL.0000000000004485.

24. Puñet-Ortiz J, Hervás-García JV, Teniente-Serra A et al. Monitoring CD49d receptor occupancy: a method to optimize and personalize natalizumab therapy in multiple sclerosis patients. Cytometry B Clin Cytom 2018; 94(2): 327–333. doi: 10.1002/ cyto.b.21527.

25. Zhovtis Ryerson L, Foley J, Chang I et al. Risk of natalizumab- associated PML in patients with MS is reduced with extended interval dosing. Neurology 2019; 93(15): e1452–e1462. doi: 10.1212/ WNL.0000000000008 243.

26. Souhrn údajů o přípravku Tysabri. [online]. Dostupné z URL: https:/ / www.bio gen.com.cz/ content/ dam/ corporate/ cs_CZ/ pdfs/ Products/ September2021/ VPOIS-Tysabri- 300- mg-inf-cnc-sol-SPC-08-2021.pdf.

27. Bomprezzi R, Pawate S. Extended interval dosing of natalizumab: a two-center, 7-year experience. Ther Adv Neurol Disord 2014; 7(5): 227–231. doi: 10.1177/ 1756285614540224.

28. Chang I, Muralidharan KK, Campbell N et al. Modeling the effi cacy of natalizumab in multiple sclerosis patients who switch from every-4-week dosing to extended- interval dosing. J Clin Pharmacol 2021; 61(3): 339–348. doi: 10.1002/ jcph.1737.

29. Petržalka M, Meluzínová E, Mojžíšová H et al. Efektivita prodlouženého dávkovacího intervalu natalizumabu u pacientů s roztroušenou sklerózou. Cesk Slov Neurol N 2020; 83/ 116(1): 79–83. doi: 10.14735/ amcsnn202 079.

30. Yamout BI, Sahraian MA, Ayoubi NE et al. Effi cacy and safety of natalizumab extended interval dosing. Mult Scler Relat Disord 2018; 24: 113–116. doi: 10.1016/ j.msard.2018.06.015.

31. Zhovtis Ryerson L, Frohman TC, Foley J et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016; 87(8): 885–889. doi: 10.1136/ jnnp-2015-312940.

32. Hamuro L, Kijanka G, Kinderman F et al. Perspectives on subcutaneous route of administration as an immunogenicity risk factor for therapeutic proteins. JPharmSci2017; 106(10): 2946–2954. doi: 10.1016/ j.xphs.2017.05. 030.

33. Viola M, Sequeira J, Seiça R et al. Subcutaneous delivery of monoclonal antibodies: how do we get there? J Control Release 2018; 286: 301–314. doi: 10.1016/ j.jconrel. 2018.08.001.

34. Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol 2013; 4: 91. doi: 10.3389/ fphar.2013.00091.

35. Lizán L, Comellas M, Paz S et al. Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature. Patient Prefer Adherence 2014; 8: 1653–1664. doi: 10.2147/ PPA.S67253.

36. Muralidharan KK, Kuesters G, Plavina T et al. Population pharmacokinetics and target engagement of natalizumab in patients with multiple sclerosis. J Clin Pharmacol 2017; 57(8): 1017–1030. doi: 10.1002/ jcph.894.

37. Plavina T, Fox EJ, Lucas N et al. A randomized trial evaluating various administration routes of natalizumab in multiple sclerosis. J Clin Pharmacol 2016; 56(10): 1254–1262. doi: 10.1002/ jcph.707.

38. Trojano M, Ramió-Torrentà L, Grimaldi LM et al. A randomized study of natalizumab dosing regimens for relapsing- remitting multiple sclerosis. Mult Scler 2021; 27(14): 2240–2253. doi: 10.1177/ 13524585211003020.